Getty Images has buy call on with a target price of Rs 402. The current market price of Strides Pharma Science is Rs 338.65. Time period given by analyst is one year when . price can reach defined target.
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3026.83 Crore) operating in Pharmaceuticals sector.
Strides Pharma Science Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Sale of services, Export Incentives and Royalty Income for the year ending 31-Mar-2021.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 953.62 Crore, up .16 % from last quarter Total Income of Rs 952.08 Crore and up 35.86 % from last year same quarter Total Income of Rs 701.90 Crore. Company reported net profit after tax of Rs -78.94 Crore in latest quarter.
Investment Rationale
Strides Pharma Science’s (Strides) Q1FY23 performance beats estimates on all fronts. Revenue grew 36.6% YoY to Rs9.4bn (I-Sec: Rs8.7bn) led by strong growth in institutional business. US revenue grew 4.5% QoQ to US$46mn during the quarter as estimated. Institutional business grew 40.2% QoQ (+108% YoY) to Rs2bn. Higher US and institutional sales QoQ drove operating leverage, supporting the 60bps QoQ EBITDA margin improvement to 5.4% (I-Sec: 4.8%). The company has reiterated its target of achieving US sales guidance of US$250mn in FY23, to be driven by new product launches and incremental sales from the Endo Pharma portfolio. Expected recovery in the US business and reasonable valuations make the stock attractive. Maintain BUY with a revised TP of Rs402/share.
Promoter/FII Holdings
Promoters held 30.6 per cent stake in the company as of 31-Mar-2022, while FIIs owned 24.61 per cent, DIIs 13.87 per cent.
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3026.83 Crore) operating in Pharmaceuticals sector.
Strides Pharma Science Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Sale of services, Export Incentives and Royalty Income for the year ending 31-Mar-2021.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 953.62 Crore, up .16 % from last quarter Total Income of Rs 952.08 Crore and up 35.86 % from last year same quarter Total Income of Rs 701.90 Crore. Company reported net profit after tax of Rs -78.94 Crore in latest quarter.
Investment Rationale
Strides Pharma Science’s (Strides) Q1FY23 performance beats estimates on all fronts. Revenue grew 36.6% YoY to Rs9.4bn (I-Sec: Rs8.7bn) led by strong growth in institutional business. US revenue grew 4.5% QoQ to US$46mn during the quarter as estimated. Institutional business grew 40.2% QoQ (+108% YoY) to Rs2bn. Higher US and institutional sales QoQ drove operating leverage, supporting the 60bps QoQ EBITDA margin improvement to 5.4% (I-Sec: 4.8%). The company has reiterated its target of achieving US sales guidance of US$250mn in FY23, to be driven by new product launches and incremental sales from the Endo Pharma portfolio. Expected recovery in the US business and reasonable valuations make the stock attractive. Maintain BUY with a revised TP of Rs402/share.
Promoter/FII Holdings
Promoters held 30.6 per cent stake in the company as of 31-Mar-2022, while FIIs owned 24.61 per cent, DIIs 13.87 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Experience Your Economic Times Newspaper, The Digital Way!
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by